Sunvozertinib for EGFR Exon 20 Insertion NSCLC
KFF Health News followed Debbie Doppelt and her son to Shanghai for sunvozertinib. China approved it in 2023. The FDA granted accelerated approval on 2 July 2025, and it was not on the US market when the story ran on 20 October 2026. AstraZeneca announced US availability on 22 October 2026.
Key Highlights
- NMPA approval on 23 August 2023, FDA accelerated approval on 2 July 2025, and AstraZeneca’s US supply announcement on 22 October 2026
- EGFR exon 20 insertion is a different alteration from exon 19 deletion and L858R; the report has to name it
- WU-KONG6 (China, 300 mg) and WU-KONG1B (FDA efficacy population, 200 mg) are different studies and doses
- The US label requires progression on or after platinum chemotherapy. The China label also includes platinum intolerance. A first-line filing is not an approval
- Staying with the home team, treatment under a Chinese oncology team, and the personal carriage described by KFF Health News
Important Facts
- A news report that supply has started is not proof a given hospital or insurer can dispense the drug
- On 1 March 2024 the FDA approved amivantamab-vmjw for EGFR exon 20 insertion NSCLC in the United States
- ChinaMed Waypoint organises records for review and does not arrange purchase or carriage of medicine
- The Chinese oncology team judges fit. Group response rates do not predict an individual result